Sepsis has long been recognized as a quintessential medical disease leading to high morbidity and mortality in worldwide hospitalized patients. The major treatment of sepsis currently is classified as supportive care, such as infection source control, timely use of antibiotics, resuscitation, and organ dysfunction to maintain patients’ life. According to statistics published by the Global Sepsis Alliance, patients killed by sepsis are more than prostate cancer, breast cancer, and AIDS combined. However, we do not have a single treatment that consistently saves lives in sepsis patients until recently.
Patients with severe sepsis often develop symptoms of persistent inflammation, immunosuppression, and catabolic syndrome involving multiple different cell types, organ systems, and pathophysiological mechanisms. The mainstream consensus on the pathogenesis of sepsis can be summarized as excessive inflammation and immunosuppression due to the immune imbalance in response to infection. Sepsis-associated excessive inflammation is prominently featured in leukocytes, endothelial cells, cytokines, complement products, and the coagulation system, while immunosuppression is related to enhanced apoptosis of immune cells, T cell exhaustion, reprogramming of cells through epigenetic changes, and reduced expression of activating cell surface molecules.
The goal of this Research Topic is to provide a forum to advance research on the contribution of immunology to the development and progression of sepsis. Our target is to reveal the molecular mechanism of cytokine release syndrome and immuno-suppression, to develop biomarkers for early diagnosis and prognosis, and to explore innovative immunopharmacological interventions with a view to having a beneficial impact on sepsis.
We welcome Original Research, Systematic Reviews, Mini Reviews, Data Reports, Case reports and Opinions that focus on, but are not limited to, the following:
1) Mechanisms of cytokine release syndrome and immuno-suppression;
2) Mechanisms of multiple organ dysfunction;
3) T-cell dysfunction and depletion;
4) Therapeutic strategies for immune checkpoints;
5) Metabolic regulation of immune function imbalance;
6) The multi-omics landscape during the development of sepsis;
7) Pathogenic mechanisms of pathogenic microorganisms;
8) Biomarkers for early diagnosis and prognosis of sepsis;
9) Monoclonal antibody inhibitor therapies for sepsis.
Sepsis has long been recognized as a quintessential medical disease leading to high morbidity and mortality in worldwide hospitalized patients. The major treatment of sepsis currently is classified as supportive care, such as infection source control, timely use of antibiotics, resuscitation, and organ dysfunction to maintain patients’ life. According to statistics published by the Global Sepsis Alliance, patients killed by sepsis are more than prostate cancer, breast cancer, and AIDS combined. However, we do not have a single treatment that consistently saves lives in sepsis patients until recently.
Patients with severe sepsis often develop symptoms of persistent inflammation, immunosuppression, and catabolic syndrome involving multiple different cell types, organ systems, and pathophysiological mechanisms. The mainstream consensus on the pathogenesis of sepsis can be summarized as excessive inflammation and immunosuppression due to the immune imbalance in response to infection. Sepsis-associated excessive inflammation is prominently featured in leukocytes, endothelial cells, cytokines, complement products, and the coagulation system, while immunosuppression is related to enhanced apoptosis of immune cells, T cell exhaustion, reprogramming of cells through epigenetic changes, and reduced expression of activating cell surface molecules.
The goal of this Research Topic is to provide a forum to advance research on the contribution of immunology to the development and progression of sepsis. Our target is to reveal the molecular mechanism of cytokine release syndrome and immuno-suppression, to develop biomarkers for early diagnosis and prognosis, and to explore innovative immunopharmacological interventions with a view to having a beneficial impact on sepsis.
We welcome Original Research, Systematic Reviews, Mini Reviews, Data Reports, Case reports and Opinions that focus on, but are not limited to, the following:
1) Mechanisms of cytokine release syndrome and immuno-suppression;
2) Mechanisms of multiple organ dysfunction;
3) T-cell dysfunction and depletion;
4) Therapeutic strategies for immune checkpoints;
5) Metabolic regulation of immune function imbalance;
6) The multi-omics landscape during the development of sepsis;
7) Pathogenic mechanisms of pathogenic microorganisms;
8) Biomarkers for early diagnosis and prognosis of sepsis;
9) Monoclonal antibody inhibitor therapies for sepsis.
